Myocardialis infarctus utáni szekunder prevenció.

Translated title of the contribution: Secondary prevention after myocardial infarction

Research output: Contribution to journalArticle

Abstract

The management of acute myocardial infarction has been revolutionized in the past decade. Advances in pharmacological and mechanical reperfusion therapy have improved the survival of patients who experience myocardial infarction. Although revascularisation techniques have been shown to reduce infarct size and in-hospital mortality, patients recovering from myocardial infarction are still at increased risk for reinfarction, congestive heart failure, and sudden death. Despite impressive technological advances, lifestyle modification and pharmacological interventions remain the key components of secondary prevention after myocardial infarction. Although the concept of secondary prevention of reinfarction and death has been investigated vigorously for several decades, preventive therapy has been seriously underused by physicians. The aim of this paper is to provide a comprehensive, evidence-based overview of secondary prevention postmyocardial infarction clinical trials, in the hope of improving the utilization of effective therapies in patients with coronary heart disease.

Original languageHungarian
Pages (from-to)2117-2128
Number of pages12
JournalOrvosi Hetilap
Volume143
Issue number37
Publication statusPublished - Sep 15 2002

Fingerprint

Secondary Prevention
Myocardial Infarction
Hope
Pharmacology
Sudden Death
Hospital Mortality
Infarction
Reperfusion
Coronary Disease
Life Style
Therapeutics
Heart Failure
Clinical Trials
Physicians
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Myocardialis infarctus utáni szekunder prevenció. / Czuriga, I.

In: Orvosi Hetilap, Vol. 143, No. 37, 15.09.2002, p. 2117-2128.

Research output: Contribution to journalArticle

@article{85695db0405f47879c22a123d79a1b97,
title = "Myocardialis infarctus ut{\'a}ni szekunder prevenci{\'o}.",
abstract = "The management of acute myocardial infarction has been revolutionized in the past decade. Advances in pharmacological and mechanical reperfusion therapy have improved the survival of patients who experience myocardial infarction. Although revascularisation techniques have been shown to reduce infarct size and in-hospital mortality, patients recovering from myocardial infarction are still at increased risk for reinfarction, congestive heart failure, and sudden death. Despite impressive technological advances, lifestyle modification and pharmacological interventions remain the key components of secondary prevention after myocardial infarction. Although the concept of secondary prevention of reinfarction and death has been investigated vigorously for several decades, preventive therapy has been seriously underused by physicians. The aim of this paper is to provide a comprehensive, evidence-based overview of secondary prevention postmyocardial infarction clinical trials, in the hope of improving the utilization of effective therapies in patients with coronary heart disease.",
author = "I. Czuriga",
year = "2002",
month = "9",
day = "15",
language = "Hungarian",
volume = "143",
pages = "2117--2128",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "37",

}

TY - JOUR

T1 - Myocardialis infarctus utáni szekunder prevenció.

AU - Czuriga, I.

PY - 2002/9/15

Y1 - 2002/9/15

N2 - The management of acute myocardial infarction has been revolutionized in the past decade. Advances in pharmacological and mechanical reperfusion therapy have improved the survival of patients who experience myocardial infarction. Although revascularisation techniques have been shown to reduce infarct size and in-hospital mortality, patients recovering from myocardial infarction are still at increased risk for reinfarction, congestive heart failure, and sudden death. Despite impressive technological advances, lifestyle modification and pharmacological interventions remain the key components of secondary prevention after myocardial infarction. Although the concept of secondary prevention of reinfarction and death has been investigated vigorously for several decades, preventive therapy has been seriously underused by physicians. The aim of this paper is to provide a comprehensive, evidence-based overview of secondary prevention postmyocardial infarction clinical trials, in the hope of improving the utilization of effective therapies in patients with coronary heart disease.

AB - The management of acute myocardial infarction has been revolutionized in the past decade. Advances in pharmacological and mechanical reperfusion therapy have improved the survival of patients who experience myocardial infarction. Although revascularisation techniques have been shown to reduce infarct size and in-hospital mortality, patients recovering from myocardial infarction are still at increased risk for reinfarction, congestive heart failure, and sudden death. Despite impressive technological advances, lifestyle modification and pharmacological interventions remain the key components of secondary prevention after myocardial infarction. Although the concept of secondary prevention of reinfarction and death has been investigated vigorously for several decades, preventive therapy has been seriously underused by physicians. The aim of this paper is to provide a comprehensive, evidence-based overview of secondary prevention postmyocardial infarction clinical trials, in the hope of improving the utilization of effective therapies in patients with coronary heart disease.

UR - http://www.scopus.com/inward/record.url?scp=17144474113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144474113&partnerID=8YFLogxK

M3 - Article

C2 - 12434627

AN - SCOPUS:17144474113

VL - 143

SP - 2117

EP - 2128

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 37

ER -